Quick Answer
Cocrystal Pharma, Inc. reported Operating Income of -$9.02 million for fiscal year 2025.
Cocrystal Pharma, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$9.02M | +49.6% |
| 2024 | -$17.88M | +3.7% |
| 2023 | -$18.56M | +52.2% |
| 2022 | -$38.83M | -173.0% |
| 2021 | -$14.22M | -48.4% |
| 2020 | -$9.59M | +80.2% |
| 2019 | -$48.41M | +23.1% |
| 2018 | -$62.92M | -661.6% |
| 2017 | -$8.26M | +92.2% |
| 2016 | -$105.82M | -96.1% |
| 2015 | -$53.95M | -830.3% |
| 2014 | -$5.80M | -42.1% |
| 2013 | -$4.08M | -59.8% |
| 2012 | -$2.55M | +34.3% |
| 2011 | -$3.89M | -12029.8% |
| 2010 | -$32.0K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.09M | +58.6% | +0.9% |
| June 30, 2025 | -$2.11M | +61.3% | +10.0% |
| March 31, 2025 | -$2.34M | +43.7% | +53.6% |
| September 30, 2024 | -$5.04M | -13.5% | +7.5% |
| June 30, 2024 | -$5.45M | -25.6% | -31.0% |
| March 31, 2024 | -$4.16M | +18.6% | +6.4% |
| September 30, 2023 | -$4.44M | +22.0% | -2.4% |
| June 30, 2023 | -$4.34M | +82.2% | +15.1% |
- Cocrystal Pharma, Inc. showed an increase of +49.6% in Operating Income compared to the prior fiscal year.
- Over the 2010–2025 period, Cocrystal Pharma, Inc.’s operating income has declined by 28044.8% (from -$32.0 thousand to -$9.02 million).
- The most recent figure is from Cocrystal Pharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: